Advertisement

Sepsis pp 307-313 | Cite as

Is there a Place for Monoclonal Antibodies Against Endotoxin in the Therapy of Sepsis?

  • L. Eidelman
  • C. L. Sprung
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 18)

Abstract

Sepsis remains the leading cause of mortality in critically ill patients. The naive belief that the introduction of new, more potent antibiotics will be sufficient to deal with the problem of infections has been discarded. Gram-negative sepsis is associated with a particularly high morbidity and mortality estimated between 20% and 75% [1–3]. Some characteristic features of gram-negative bacteria are believed to be reponsible for the not infrequent development of multiple organ failure and death despite the use of potent antibacterial compounds to sensitive microorganisms. The intravenous injection of endotoxin causing the typical clinical manifestations of gram-negative bacteremia including fever, shock-, leukopenia and/or leukocytosis and disseminated intravascular coagulation was revealed as far back as 1942 [4]. Endotoxin has been proposed as a major causal factor in the development of gram-negative sepsis [5]. Bacteremia and septic shock are associated with the release of endotoxin into the circulation which is believed to activate the biologic cascade involving tumor necrosis factor (TNF) and other cytokines such as interleukin-1 (IL-1) and interleukin-6 (IL-6). As the development of many systemic septic responses can be explained by the action of these substances, immunotherapy directed against endotoxin has been suggested as a possible method to decrease morbidity and mortality in patients with sepsis.

Keywords

Septic Shock Adult Respiratory Distress Syndrome Federal Drug Administration Naive Belief Antiendotoxin Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sprung CL, Caralis PV, Marcial EH et al (1984) The effects of high-dose corticosteroids in patients with septic shock. N Engl J Med 311:1137–1143PubMedCrossRefGoogle Scholar
  2. 2.
    Bone RC, Fisher CJ Jr, Clemmer TP et al (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653–658PubMedCrossRefGoogle Scholar
  3. 3.
    The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effects of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Eng J Med 317:659–665CrossRefGoogle Scholar
  4. 4.
    Favorite GO, Morgan HR (1942) Effects produced by intravenous injection in man of a toxic antigenic material derived from Eberthella typhosa: clinical hematological, chemical and serological studies. J Clin Invest 21:589–599PubMedCrossRefGoogle Scholar
  5. 5.
    Hamill RJ, Maki DG (1986) Endotoxin shock in man caused by gram-negative bacilli. Etiology, clinical features, diagnosis, natural history and prevention In: Proctor RA (ed) Handbook of endotoxin. Elsevier, Amsterdam, pp 55–126Google Scholar
  6. 6.
    Michie HR, Manogue KR, Spriggs DR et al (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486PubMedCrossRefGoogle Scholar
  7. 7.
    Revhaug A, Michie HR, Manson J McK et al (1988) Inhibition of cyclooxygenase attenuates the metabolic response to endotoxin in humans. Arch Surg 123:162–170PubMedCrossRefGoogle Scholar
  8. 8.
    Suffredini AF, Fromm RE, Parker MM et al (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321:280–287PubMedCrossRefGoogle Scholar
  9. 9.
    van Deventer SJH, Buller HR, ten Cate JW et al (1988) Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet 1:605–608PubMedCrossRefGoogle Scholar
  10. 10.
    Danner RL, Elin RJ, Hosseini JM et al (1991) Endotoxemia in human septic shock. Chest 99:169–175PubMedCrossRefGoogle Scholar
  11. 11.
    Wortel CH, von der Mohlen MAM, van Deventer SJH et al (1992) Effectiveness of a human monoclonal anti-endotoxin antibody (HA-IA) in gram-negative sepsis. Relationship to endotoxin and cytokine levels. J Infect Dis 166:1367–1374Google Scholar
  12. 12.
    Parsons PE, Worthen GS, Moore EE, et al (1989) The association of circulating endotoxin with the development of the adult respiratory distress syndrome. Am Rev Respir Dis 140:294–301PubMedCrossRefGoogle Scholar
  13. 13.
    Brandtzaeg P, Kierulf P, Gaustad P et al (1989) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195–204PubMedCrossRefGoogle Scholar
  14. 14.
    Kirkland TN, Ziegler EJ (1984) An immunoprotective monoclonal antibody to lipopolysaccharide. J Immunol 132:2590–2592PubMedGoogle Scholar
  15. 15.
    Baumgartner JD, Heumann D, Gerain J et al (1990) Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin-6: comparison of O side chain specific antibodies with core LPS antibodies. J Exp Med 171:889–896PubMedCrossRefGoogle Scholar
  16. 16.
    McCabe WR, DeMaria A Jr, Berberich H et al (1988) Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re Chemotype) mutant. J Infect Dis 158:291–300PubMedCrossRefGoogle Scholar
  17. 17.
    Ziegler EJ, Douglas H, Sherman JE et al (1973) Treatment of E. coli and Klebsiella bacteremia in agranulocytopenic animals with antiserum to a UDP-Gal epimerase-deficient mutant. J Immunol 111:433–438Google Scholar
  18. 18.
    Ziegler EJ, McCutchan JA, Fierer J et al (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225–1230PubMedCrossRefGoogle Scholar
  19. 19.
    Baumgartner JD, Glauser MP, McCutchan JA et al (1985) Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet ii: 59–63CrossRefGoogle Scholar
  20. 20.
    Calandra T, Glauser MP, Schellekens J et al (1988) Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, doubleblind, randomized trial. J Infect Dis 158:312–319PubMedCrossRefGoogle Scholar
  21. 21.
    Ziegler EJ, Fisher CJ, Sprung CL et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-IA human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429–436Google Scholar
  22. 22.
    Dunn Dl, Ewald DC, Chandan N et al (1986) Immunotherapy of gram-negative bacterial sepsis: a single murine monoclonal antibody provides cross-genera protection. Arch Surg 121:58–62PubMedCrossRefGoogle Scholar
  23. 23.
    Teng NNH, Kaplan HS, Herbert JM et al (1985) Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790–1794PubMedCrossRefGoogle Scholar
  24. 24.
    Warren HS, Danner Rl, Munford RS (1992) Anti-endotoxin monoclonal antibodies. N Engl J Med 326:1153–1157PubMedCrossRefGoogle Scholar
  25. 25.
    Baumgartner JD, Heumann D, Glauser MP (1991) The HA-IA monoclonal antibody for gram-negative sepsis. N Engl J Med 325:281–282Google Scholar
  26. 26.
    Ziegler EJ, Smith CR (1992) Anti-endotoxin monoclonal antibodies. N Engl J Med 326:1165PubMedGoogle Scholar
  27. 27.
    Ziegler EJ (1988) Protective antibody to endotoxin core: the emperor’s new clothes?. J Infect Dis 158:286–290PubMedCrossRefGoogle Scholar
  28. 28.
    Krieger JI, Fletcher RC, Siegel SA et al (1992) HA-IA (Centoxin TM), a human monoclonal IgM anti-endotoxin antibody, mediates immune adherence of endotoxin via CR1 of human RBCs and neutrophils. Clin Res 40:286A (abstract)Google Scholar
  29. 29.
    Siegel JP, Stein KE, Zoon KC (1992) Anti-endotoxin monoclonal antibodies. N Engl J Med 327:890–891Google Scholar
  30. 30.
    Sprung CL, Eidelman LA (1993) Monoclonal antibodies, new technologies and critical care medicine (editorial). Crit Care Med (in press)Google Scholar
  31. 31.
    Inglis TJJ, Lacey RW, Kay E et al (1993) Monoclonal antiendotoxin agent HA-1A (Centoxin). Lancet 341:303PubMedCrossRefGoogle Scholar
  32. 32.
    Quezado ZMN, Natanson C, Ailing DW et al (1993) A controlled trial of HA-1A in a canine model of gram-negative bacteremia. JAMA 269:2221–2227PubMedCrossRefGoogle Scholar
  33. 33.
    Kett DH, Quartin AA, Pena MA et al (1992) Hemodynamic effects of HA-1A monoclonal antibody to endotoxin. Crit Care Med 20:S100 (abstract)Google Scholar
  34. 34.
    Siegel SA, Evans ME, Pollack M et al (1993) Antibiotics enhance binding by human lipid A-reactive monoclonal antibody HA-1A to smooth gram-negative bacteria. Infect Immun 61:512–519PubMedGoogle Scholar
  35. 35.
    Greenman RL, Schein RMH, Martin MA et al (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097–1102PubMedCrossRefGoogle Scholar
  36. 36.
    Wenzel R, Bone R, Fein A et al (1991) Results of a second double-blinded, randomized, controlled trial of antiendotoxin antibody E5 in gram-negative sepsis. In: Program and abstracts of the 31st interscience conference on antimicrobial agents and chemotherapy. 29 Sept–2 Oct, Chicago, IL, p294Google Scholar
  37. 37.
    Barriere SL, Gugleilmo BJ (1992) Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Clin Pharm 11:223–235PubMedGoogle Scholar
  38. 38.
    Fink MP (1993) Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide. Crit Care Med 21:S32–S39PubMedCrossRefGoogle Scholar
  39. 39.
    Caplan ES (1993) Role of immunomodulator therapy in sepsis. Am J Surg 165:20S–25SPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • L. Eidelman
  • C. L. Sprung

There are no affiliations available

Personalised recommendations